▶ Full Post Text
**TL;DR:** Doximity (DOCS) is a digital platform used by 80% of U.S. physicians for collaboration, telehealth, and medical news. They make money by charging pharma companies for targeted marketing access. The stock sold off because pharma clients delayed ad budgets due to regulatory uncertainty around drug pricing (MFN deals). Wall Street panicked, but the fundamentals remain pristine: 89.75% gross margins, 23.59% ROIC, $724M in net cash, and management just authorized a $500M buyback program. Trading at $24 vs. intrinsic value of $28.44 (15.6% margin of safety). I think the market is overreacting to temporary headwinds.
## the business
DOCS built the digital town square for American doctors. 80% of all U.S. physicians use it to collaborate with colleagues, manage telehealth visits, read medical research, and handle their on-call schedules. The doctors don't pay anything. Instead, Doximity charges pharmaceutical companies and health systems for targeted digital marketing and workflow tools.
What caught my attention is the recurring revenue model. 95% of their revenue is subscription-based, and once a pharma client integrates Doximity into their annual budget, they tend to stay and spend more. Net Revenue Retention is 112%, which jumps to 117% for their top 20 customers.
## the numbers
| | |
|---|---|
| Operating Cash Flow | $315.42M |
| Stock-Based Compensation | -$102.95M |
| Working Capital Change | $31.51M |
| Maintenance CapEx (5yr avg) | -$9.12M |
| WC Reinvest | -$3.48M |
| **Owner Earnings** | **$231.38M** |
| Shares Outstanding (Diluted) | 188.88M |
| **Owner Earnings Per Share** | **$1.23** |
I use a 5-year smoothed CapEx figure because their maintenance spending is lumpy year to year. Over the last five years, CapEx averaged 1.43% of revenue. This is an incredibly asset-light business.
**Quality metrics:**
- ROIC: 23.59%
- 5-year Owner Earnings CAGR: 54.40%
- Gross Margin: 89.75%
- Operating Margin: 38.46%
- Recurring Revenue: ~95%
## the balance sheet
They have $735.13M in liquid assets and only $10.69M in debt. Net cash sits at $724.44M, or $3.84 per share. The enterprise value is $3.55B, which gives you an EV-to-Owner-Earnings multiple of 15.3x.
## why it's cheap
The market sold off hard because revenue guidance dropped from 20% growth to roughly 10%. The reason: 16 of their top 20 pharma clients delayed their annual ad budgets late in the year while waiting for the White House to finalize Most Favored Nation drug pricing deals. Wall Street hates uncertainty, so the stock tanked.
Adding to the noise, CFO Anna Bryson resigned in mid-April 2026 while on medical leave. Truist and Evercore downgraded the stock citing "reduced visibility" in pharma ad spending.
## why I think the market is wrong
January 2026 pharma bookings hit record highs. Management said on the Q3 call this is a timing issue, not a structural loss of clients. They expect to exit the calendar year as a double-digit grower once the frozen budgets thaw.
More importantly, if the moat was eroding, you'd see margins compress. Instead, gross margins are 89.75% (up from the 5-year average of 88.02%), and operating margins are 38.46% (up from 33.05% in 2022). ROIC is 23.59%, above the historical average of 18.91%.
Management's response tells you what they think the business is worth. They authorized a $500M open-ended buyback program and repurchased $367.9M in stock over the trailing twelve months. That's an 8.62% buyback yield. They're cannibalizing the float at cheap prices instead of chasing acquisitions.
## valuation
| | |
|---|---|
| Owner Earnings Per Share | $1.23 |
| Multiple | 20x |
| Business Value | $24.60 |
| Net Cash Per Share | $3.84 |
| **Intrinsic Value** | **$28.44** |
| Current Price | $24.00 |
| **Margin of Safety** | **15.6%** |
I'm using 20x because this is a mature, high-ROIC franchise with a dominant network effect moat, not a hyper-growth SaaS startup. The user acquisition phase is behind them (you can't grow past 80% market penetration). Future growth comes from increasing revenue per user, which grew 22% last year.
## what worries me
A few things keep me honest here:
Market saturation is the real structural risk. They already have 80% of U.S. physicians on the platform. The total addressable market for user growth is capped. If revenue per user stops growing, or if pharma clients permanently shift budgets away from digital channels, the thesis breaks.
The AI competition narrative feels overblown to me. Startups like OpenEvidence are trying to build a "ChatGPT for doctors," but Doximity already rolled out their AI suite (DocsGPT) to 100 top health systems covering 180,000 prescribers in a single quarter. They have the distribution, the HIPAA infrastructure, and a "Peer Check" program with 10,000 medical experts verifying AI outputs. That's hard to displace.
## where I come out
I think this is a high-quality business trading at a discount because of temporary regulatory noise. The fundamentals remain strong. A business doesn't post 89.75% gross margins and 23.59% ROIC if its moat is broken.
That said, it's a mid-cap with lumpy pharma budgets and a market saturation ceiling baked into the valuation. I hold a position.
*Disclosure: I hold a position in DOCS. Hard data from filings, AI-assisted writing, personal review and position. This is not financial advice.*